Finance

Lists
Why is XERS down 4,22%?
Dive Deeper
XERS:NASDAQ
Xeris Biopharma Holdings Inc
9,77 USD
-4,22%
(-0,43) 1D
9,82 USD
+0,51% (+0,050)
After hours
Closed: 14-окт., 16:00:01 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for XERS...
Open
10,08 USD
High
10,39 USD
Low
9,73 USD
Mkt. cap
1,78 млд
Avg. vol.
2,88 млн
Volume
2,37 млн
52-wk high
11,33 USD
52-wk low
5,25 USD
EPS
-0,11 USD
Beta
0,68
Shares outstanding
182,32 млн
No. of employees
435
Open
10,08 USD
High
10,39 USD
Low
9,73 USD
Mkt. cap
1,78 млд
Avg. vol.
2,88 млн
Volume
2,37 млн
52-wk high
11,33 USD
52-wk low
5,25 USD
EPS
-0,11 USD
Beta
0,68
Shares outstanding
182,32 млн
No. of employees
435
News stories
From web sources and news partners
About Xeris Biopharma Holdings Inc
CEO-
Employees435
Founded2005
HeadquartersЧикаго, Иллинойс, Америка Кошмо Штаттары
SectorPharmaceutical industry
Analyst ratings
Based on 6 analysts giving stock ratings to XERS in the past 3 months
Strong buy
Buy
5
Hold
1
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for XERS in the last 3 months.
Highest
Current 9,77 USD
18,00 USD (+84,24%)
Average
13,00 USD (+33,06%)
Lowest
8,00 USD (-18,12%)
Analyst
Recommendation
Action
Price target
Projected
Date
Jenna Davidner
Barclays
Buy
Maintained
14,00 USD
+43,3%
10/06/2026
Chase Knickerbocker
Craig-Hallum
Buy
Maintained
12,00 USD
+22,8%
09/29/2026
Brandon Folkes
H.C. Wainwright
Buy
Maintained
10,00 USD
+2,4%
09/21/2026
Unknown Analyst
Oppenheimer
Buy
Reiterated
18,00 USD
+84,2%
09/10/2026
David Amsellem
Piper Sandler
Hold
Reiterated
8,00 USD
-18,1%
09/10/2026
Roanna Ruiz
Leerink Partners
Buy
Reiterated
16,00 USD
+63,8%
09/10/2026
Last report
2026-ж., 6-авг.
Fiscal period
Q2 2026
-0,00 USD / 0,00 USD
-172,00%miss
Revenue / Est. (USD)
92,10 млн / 90,12 млн
+2,19%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
74,38 млн
85,81 млн
83,13 млн
92,10 млн
Cost of goods sold
11,00 млн
10,95 млн
10,57 млн
12,51 млн
Cost of revenue
11,00 млн
10,95 млн
10,57 млн
12,51 млн
Research and development expenses
7,48 млн
7,87 млн
8,78 млн
10,67 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
46,46 млн
47,50 млн
53,14 млн
61,04 млн
Operating expense
56,65 млн
58,09 млн
64,64 млн
74,42 млн
Total operating expenses
67,65 млн
69,03 млн
75,21 млн
86,93 млн
Operating income
6,73 млн
16,77 млн
7,92 млн
5,17 млн
Other non operating income
-
-
-
-
EBT including unusual items
621,00 миң
11,08 млн
2,23 млн
-31,10 млн
EBT excluding unusual items
621,00 миң
11,08 млн
2,23 млн
-319,00 миң
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
621,00 миң
11,08 млн
2,23 млн
-31,10 млн
Net profit margin
0,83%
12,91%
2,69%
-33,77%
Earnings per share
-
0,06
0,01
-0,00
Interest and investment income
1,16 млн
1,46 млн
1,20 млн
1,46 млн
Interest expense
-7,27 млн
-7,15 млн
-6,88 млн
-6,95 млн
Net interest expenses
-6,11 млн
-5,69 млн
-5,68 млн
-5,49 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
9,78 млн
19,82 млн
10,96 млн
8,21 млн
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google колдонмолору